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ABSTRACT
Late SV40 factor 3 (LSF), a transcription factor, contributes to human 
hepatocellular carcinoma (HCC). However, decreased expression level of LSF in skin 
melanoma compared to that in benign melanocytic tumors and nevi in mice and 
humans was found in this study. Anchorage-dependent and -independent growth 
of melanoma cells was suppressed by LSF overexpression through an increased 
percentage of G1 phase cells and an increased p21CIP1 expression level in vitro and 
in vivo. Anchorage-dependent growth in LSF-overexpressed melanoma cells was 
promoted by depletion of LSF in the LSF-overexpressed cells. Integrated results of 
our EMSA and chromatin immunoprecipitation assays showed binding of LSF within 
a 150-bp upstream region of the transcription start site of p21CIP1 in melanoma 
cells. Taken together, our results suggest potential roles of LSF as a growth regulator 
through control of the transcription of p21CIP1 in melanocytes and melanoma cells as 
well as a biomarker for nevus.
INTRODUCTION
Approximately 50% of human melanomas have 
BRAF mutations [1]. In the most common BRAF mutation 
(90% of cases), valine 600 is substituted by glutamic 
acid (V600E) [2]. A previous study suggested that the 
expression of oncogenic BRAFV600E in various benign 
lesions including human nevus cells contributes to their 
stable growth arrest of oncogene-induced senescence 
(OIS) [3]. 
We previously established Metallothionein-I/RFP-
RET transgenic mice (RET-mice) that spontaneously 
develop systemic skin melanosis, benign melanocytic 
tumors and melanoma metastasizing to distant organs [4, 
5]. Both RET-mice and a Mel-ret murine melanoma cell 
line from the tumor of a RET-mouse [6] might be strong 
tools for analyzing the molecular mechanism of melanoma 
growth.
Recent studies have shown that Late SV40 factor 3 
(LSF), a transcription factor, functions as an oncogene in 
hepatocellular carcinomas (HCC) [7-9]. Previous studies 
suggest that increased expression level of LSF promotes 
malignant progression. In this study, we not only found 
opposite roles of LSF in melanoma compared to those 
previously reported in HCC but also revealed a novel 




LSF expression levels in tumors of RET-mice
Corresponding to our results of preliminary DNA 
microarray analysis using a benign melanocytic tumor 
and a primary melanoma in RET-mice, our RT-qPCR 
analysis showed that levels of Lsf transcript expression in 
benign tumors from RET-mice (lanes 1-6 in Figure 1A) 
were about 3-12-fold higher than those in melanomas 
from RET-mice (lanes 7-10 in Figure 1A). Lsf protein 
expression was detectable in benign tumors from RET-
mice (lanes 1-4 in Figure 1B and 1C), but the expression 
in melanomas from RET-mice was undetectably low 
Figure 1: Lsf expression levels in mice. A.-F. Results of RT-qPCR A., E., F., immunoblot B. and immunohistochemical C., D. 
analyses for benign melanocytic tumors (lanes 1-6 in A., lanes 1-4 in B., and C., lane 1 in E. and F.) and melanomas (lanes 7-10 in A., lanes 
5-6 in B., D., lane 2 in E. and F.) from RET-mice, for indicated organs from wild-type mice (lanes 3-16 in E.), and for melanoma cell lines 
(lanes 3-7 in F.) of B16 and Mel-ret [6]. Hprt (A., E., F.) and α-Tubulin B. were used as internal controls in RT-qPCR and immunoblot 
analyses, respectively. Results (mean ± SD) are representative of three independent experiments. 
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(lanes 5 and 6 in Figure 1B and Figure 1D). In addition, 
levels of Lsf transcript expression in normal murine tissues 
(lanes 3-16 in Figure 1E) and other murine melanoma cells 
including B16 cells and Mel-ret cells (lanes 3-7 in Figure 
1F) were lower than those in benign melanocytic tumors 
and melanoma from RET-mice (lane 2 in Figure 1E and 
1F), whereas Lsf has been reported to be ubiquitously 
expressed in normal mouse tissues [10]. These results 
suggest that Lsf expression level in melanoma is lower 
than that in benign melanocytic tumors in mice.
Levels of LSF expression in human nevi and 
melanomas
Levels of LSF protein expression were examined 
in 24 nevus cell nevi, 55 primary melanomas and 20 
metastatic melanomas in lymph nodes of humans. After 
confirming that LSF protein was expressed in nevus and 
melanoma cells but not in stroma cells (Figure S1), all 
of the samples were classified into three groups (weak/
negative, moderate and strong) by the signal intensity 
of LSF protein (Figure 2A-2F), according to the method 
Figure 2: LSF expression levels in melanocytic tumors in humans. A.-F. Representative signal scores for both nevus cell nevus 
A.-C. and melanoma D.-F. samples are shown as negative/weak (A. and D.), moderate (B. and E.) and strong (C. and F.). Dotted squares 
show the areas magnified in the inset. Scale bar, 200 µm. G. Percentages classified as negative/weak (white), moderate (light gray) and 
strong (dark gray) LSF protein expression levels in nevi and primary and metastatic melanomas are shown. Significantly different (**, p 
< 0.01) from nevi by Fisher’s exact test. 
Oncotarget2382www.impactjournals.com/oncotarget
previously reported [11, 12]. As shown in Figure 2G, 42% 
of nevus cell nevi, 22% of primary melanomas and 15% of 
metastatic melanomas were classified as strong intensity. 
Statistical analysis by Fisher’s exact test showed a 
significantly (p < 0.01) decreased expression level of LSF 
protein in primary and metastatic melanomas compared to 
that in nevus cell nevi. These results again suggest a lower 
level of LSF expression in melanoma compared to that in 
benign melanocytic tumors in humans.
Figure 3: Effect of LSF overexpression on anchorage-independent growth of SK-Mel28 melanoma cells in vitro. A. 
Levels of anchorage-dependent growth (mean ± SD) in control tSK-DsR and tSK-DsR-LSF cells, which had been transiently transfected 
with the indicated amounts of an empty vector and DsRed-LSF expression vector, respectively, were quantified by crystal violet staining 
after confirming LSF protein expression levels by immunoblot analysis. B. Results of cell cycle analysis by flow cytometry in control 
tSK-DsR cells (black bars) and tSK-DsR-LSF cells (gray bars) are shown. Histograms and a graph showing percentages (mean ± SD) of 
G1, S and G2/M phases are shown. C., D. Immunoblot detection of LSF expression C. and anchorage-dependent growth (mean ± SD) 
D. in control tSK-DsR cells (black bars) and tSK-DsR-LSF cells (gray bars), which had been stably transfected with an empty vector and 
DsRed-LSF expression vector, respectively. Arrow, endogenous LSF; arrowhead, DsRed-fused LSF. Significantly different (**, p < 0.01) 
from the control by Student’s t-test.
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LSF overexpression-mediated G1/S arrest in 
melanoma cells in vitro
Anchorage-dependent growth was examined in 
human SK-Mel28 melanoma (tSK-DsR-LSF) cells 
transiently overexpressing DsRed-LSF fusion protein to 
elucidate the molecular function. Our cell proliferation 
assay using crystal violet showed that anchorage-
dependent growth in tSK-DsR-LSF cells was decreased 
by about 19-40% compared to that in control human 
SK-Mel28 melanoma (tSK-DsR) cells transiently 
overexpressing DsRed protein (Figure 3A). Flow 
cytometric analysis showed that 62% in G1 phase of 
control tSK-DsR cells was increased to 80.5% in G1 phase 
of tSK-DsR-LSF cells (Figure 3B). Correspondingly, 
anchorage-dependent growth of human SK-Mel28 
melanoma (sSK-DsR-LSF) cells stably overexpressing 
DsRed-LSF fusion protein was significantly suppressed 
compared to that of control human SK-Mel28 melanoma 
(sSK-DsR) cells stably overexpressing DsRed protein 
(Figure 3C and 3D). Then 3 kinds of LSF-depleted sSK-
DsR-LSF cells transfected with 3 kinds of siRNAs for 
LSF and control NG-sSK-DsR-LSF cells transfected with 
negative control siRNA were developed. After confirming 
decreased levels of LSF transcript and protein expression 
in LSF-depleted sSK-DsR-LSF (1), (2) and (3) cells 
compared to those in NG-sSK-DsR-LSF cells (Figure 
S2A, S2B), anchorage-dependent growth was examined. 
As expected, the level of anchorage-dependent growth of 
LSF-depleted sSK-DsR-LSF (2) cells was significantly 
higher than those of sSK-DsR-LSF cells and NG-sSK-
Figure 4: Effect of LSF overexpression on anchorage-independent growth of B16F10 melanoma cells in vivo. A.-I. 
Tumor volumes A. and macroscopic (B., D.) and microscopic (C., E., F.-I.) appearances in nude mice at 11 days after subcutaneous 
inoculation of control B16F10 melanoma cells (sB16-FLAG; n=5) (B., C., F., G.) and B16F10 cells stably overexpressing LSF (sB16-
FLAG-LSF; n=6) (D., E., H., I.). Results of HE staining (C., E.) and immunohistochemical detection of Ki67 (F., G.) and LSF (H., I.) 
for the inoculated melanoma are presented. Significantly different (**, p < 0.01) from the control by Student’s t-test. Scale bar, 100 µm. 
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DsR-LSF cells and was near to that of sSK-DsR cells 
(Figure S2C). 
Correspondingly, the percentage of G1 phase cells 
in murine B16F10 melanoma (tB16-FLAG-LSF) cells 
transiently overexpressing FLAG-LSF fusion protein was 
higher than that in control murine B16F10 melanoma 
(tB16-FLAG) cells transiently overexpressing FLAG 
protein (Figure S3A, S3B). Anchorage-dependent growth 
of murine B16F10 melanoma (sB16-FLAG-LSF) cells 
stably overexpressing FLAG-LSF fusion protein was again 
decreased compared to that of control murine B16F10 
melanoma (sB16-FLAG) cells stably overexpressing 
FLAG protein (Figure S3C, S3D).
Effect of LSF overexpression on anchorage-
independent growth of melanoma cells
Since inoculated sSK-DsR-LSF cells and control 
sSK-DsR cells did not form subcutaneous tumors in nude 
mice within two months, nude mice were inoculated with 
LSF-overexpressed sB16-FLAG-LSF cells and control 
sB16-FLAG cells. Tumor volume of inoculated LSF-
overexpressed cells (n = 6) was less than 1% of that of 
control cells (n = 5) (Figure 4A-4E). Immunohistochemical 
detection of Ki67 showed that the number of proliferating 
cells in LSF-overexpressed cells was decreased compared 
to that in control cells (Figure 4F, 4H). The level of 
angiogenesis in tumors derived from LSF-overexpressed 
cells was lower than that in tumors derived from control 
cells (Figure S4). These results showing increased LSF-
mediated decrease in angiogenesis in melanoma may 
simply reflect the difference in tumor size between sB16-
FLAG-LSF cells and sB16-FLAG cells. Further study is 
needed to clarify the direct effect of LSF on angiogenesis 
in melanoma. Our colony formation assay in vitro showed 
that anchorage-independent growth of LSF-overexpressed 
sB16-FLAG-LSF cells was suppressed compared to that 
of control sB16-FLAG cells (Figure S5A). Expression 
and phosphorylation levels of FAK and AKT protein were 
comparable between LSF-overexpressed sB16-FLAG-
LSF cells and control sB16-FLAG cells (Figure S5B). 
These results suggest that the contribution of FAK and 
AKT activities to LSF-mediated anchorage-independent 
growth in melanoma is limited. 
Figure 5: Effect of LSF overexpression on cell cycle regulators in melanoma cells. Representative results of immunoblot 
analysis for expression levels of cell cycle regulators, CDK2, CDK4, p21CIP1and p16INK4a, in SK-Mel28 cells stably overexpressing DsRed 
protein (sSK-DsR) (lanes 1 and 2) and DsRed-LSF fusion protein (sSK-DsR-LSF) (lanes 3 and 4) are presented. α-TUBULIN served as an 
internal control. Graph of relative intensities (means ± SD) of p21CIP1and p16INK4a protein expression levels obtained from three independent 
experiments are presented. Significantly different (**, p < 0.01; *, p < 0.05) from the control [sSK-DsR (Clone 9)] in each analysis of 
p21CIP1and p16INK4a by Student’s t-test. 
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Increased cell-cycle inhibitors by LSF 
overexpression
To analyze the molecular mechanism of LSF-
mediated growth in melanoma, expression levels of four 
major players in cell cycle regulation were examined in 
LSF-overexpressed sSK-DsR-LSF cells and control sSK-
DsR cells (Figure 5). Although protein expression levels 
of CDK2 and CDK4 were comparable between LSF-
overexpressed and control cells, protein expression levels 
of p21CIP1 and p16INK4a in LSF-overexpressed cells were 
5.7-7.1-fold and 1.9-2.2-fold higher than those in control 
cells, respectively (Figure 5). The increased level of 
p21CIP1 protein in LSF-overexpressed sSK-DsR-LSF cells 
was decreased in LSF-depleted sSK-DsR-LSF cells but 
not in NG-sSK-DsR-LSF cells (Figure S2D).
LSF-mediated regulation of p21CIP1 transcription 
in melanoma cells
The transcription factor LSF interacts with the 
CNRG-N6-CNRG motif in target DNAs [13-16]. Scanning 
of the p21CIP1 sequence revealed four similar motifs from 
the transcription start site to the 150-bp upstream region 
(Figure 6A), whereas the motif was not present in the 
p16INK4A promoter. These results suggest that LSF regulates 
the transcription of p21CIP1by binding to its promoter 
region. Our results of EMSA using purified recombinant 
FLAG-tagged human LSF showed that LSF binds to all 
of the four candidate regions (Figure 6B). Binding of LSF 
using probes #1 and #4 was sequence-specific because 
the band-shift was abolished by competition with cold 
oligonucleotides and by substitution of mutated probes.
Figure 6: Association of LSF with p21CIP1 promoter sequences in vitro and in vivo. A. Putative CNRG-N6-CNRG motifs in the 
region of -149 to -136 bps (#1), -120 to -107 bps (#2), -99 to -87 bps (#3) and -17 to -4 (#4) bps from the transcription start site of p21CIP1 
are shown. B. Results of the EMSA assay using putative LSF-binding (wild) and mutant DNA probes in the presence or absence of in vitro 
translated LSF and competitor oligonucleotides (cold) are shown. C. Luciferase activity (mean ± SD) by binding of LSF in the promoter 
region of p21CIP1 in control parental SK-Mel28 cells, sSK-DsR cells and sSK-DsR-LSF cells in the presence (gray) or absence (black) 
of transient depletion of LSF. D. The LSF binding of each region in the immunoprecipitates was evaluated by qPCR, and the results are 
expressed as percentage (mean ± SD) to the input. Significantly different (**, p < 0.01) from the control by Student’s t-test. 
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To determine whether LSF can induce p21CIP1 
transcription, we cloned a 1.2-kb region in the p21CIP1 
promoter containing the putative LSF binding sites into a 
luciferase reporter vector. This construct was transfected 
to parental SK-Mel28 cells and LSF-overexpressed sSK-
DsR-LSF cells. As shown in Figure 6C, luciferase activity 
in the LSF-overexpressed cells was increased compared to 
that in control parental SK-Mel28 cells and in SK-Mel28 
cells transfected with an empty vector. Co-transfection 
of the LSF siRNA with the reporter construct abolished 
the elevation of luciferase activity, suggesting functional 
relevance of LSF-mediated transactivation of p21CIP1.
Chromatin immunoprecipitation (ChIP) was 
performed to analyze the association of LSF with the 
promoter region of p21CIP1 in vivo in sSK-DsR-LSF cells. 
Cross-linked chromatin was precipitated with an antibody 
against DsRed followed by qPCR using site-specific 
primers against the putative LSF binding sites within the 
p21CIP1 promoter region. Levels of LSF binding from the 
transcription start site to the 500-bp upstream region were 
Figure 7: Effect of LSF overexpression on anchorage-dependent growth of melanocytes in vitro. (A.-C.) Levels of p21CIP1 
transcript A. and protein B. expression and anchorage-dependent growth on day 3 C. in control murine melan-a melanocytes (lane 1 in A.-
C.) and melan-a melanocytes transiently overexpressing LSF (lane 2 in A.-C.), p53 (lane 3 in A.-C.) and MITF (lane 4 in A.-C.). Results 
(means ± SD) from three independent experiments are shown in the graphs (A., C.). Results of crystal violet staining are shown in the 
photographs C.. Significantly different (**, p < 0.01; *, p < 0.05) from the control by Student’s t-test.
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5.9-12.2-fold higher than those in other regions (Figure 
6D). These results suggest that LSF regulates p21CIP1 
transcription by directly binding to specific regions of the 
p21CIP1 promoter.
LSF-mediated regulation of p21CIP1 transcription 
in melanocytes
Lastly, the effect of LSF expression on anchorage-
dependent growth was examined. Transfection efficiency 
was undetectably low in NHEM. Therefore, murine 
immortalized normal melanocytes (melan-a) were used 
(Figure 7). A previous study showed that p21 transcription 
was regulated by p53 and MITF [17]. After confirming 
that transcript and protein expression levels of p21 were 
increased in melan-a cells transiently overexpressing LSF, 
p53 and MITF compared to those in control melan-a cells 
(Figure 7A and 7B), anchorage-dependent growth was 
examined (Figure 7C). Anchorage-dependent growth was 
decreased in melan-a cells transiently overexpressing LSF, 
p53 and MITF compared to that in control melan-a cells 
(Figure 7C). These results suggest that LSF is associated 
with anchorage-dependent growth of normal melanocytes 
as well as melanoma cells. 
DISCUSSION
In this study, we first showed that the expression 
level of LSF in melanoma was decreased compared to that 
in nevi. We then showed that increased LSF expression 
levels suppressed anchorage-dependent growth and 
-independent growth of melanoma cells via regulation 
of the cell cycle with increased p21CIP1 and p16INK4a 
expression levels in vitro and in vivo. We finally provided 
evidence of binding of LSF in the promoter region of 
p21CIP1 in melanoma. 
At present, only a handful of markers have been 
identified for benign melanocytic tumors including nevi 
[18]. Spitz nevus and dysplastic nevus were also classified 
as strong intensity in accordance with the classification 
method in Figure 2 (Figure S6). LSF transcript expression 
levels in nevus cell nevi were 1.6-5.1-fold higher than 
those in melanomas and various tissues in humans (Figure 
S7). Thus, LSF is a potential diagnostic marker for benign 
melanocytic tumors in humans. 
Previous studies showed independent pathways 
of p16INK4a and p21CIP1 in BRAFV600E-mediated OIS in 
melanoma [3]. DNA-binding activity of LSF has been 
reported to be controlled via phosphorylation of LSF at 
serine 291 by ERK, which is potentially sited downstream 
of BRAFV600E [19, 20]. Taken together, our results showing 
an LSF-mediated increase in p21CIP1 expression level in 
melanocytic cells suggest that LSF contributes to an OIS 
pathway through the pathway of BRAFV600E/ERK/LSF/
p21CIP1 (Figure S8). 
In conclusion, we newly propose a potential role of 
LSF in melanocytic cells as a growth regulator as well as 
a biomarker. 
MATERIALS AND METHODS
Mice, cell lines and culture conditions
Previously established RET-mice of line 304/B6 
[4, 5] were used. Normal human epithelial melanocytes 
(NHEM) were purchased from KURABO Co. and were 
maintained in melanocyte growth medium containing 
hydrocortisone and growth supplements. G361 cells 
were provided by Cell Resource Center for Biomedical 
Research, Tohoku University. Human SK-Mel28 
melanoma cells and mouse B16 melanoma cell lines 
were purchased from the Riken Bioresource Center Cell 
Bank. The immortal melanocyte cell line melan-a was 
provided by the Wellcome Trust Cell Bank at St George’s, 
University of London. This cell line was cultured in 
RPMI-1640 medium supplemented with 10% fetal bovine 
serum (FBS) and 200 nM 12-o-tetradecanoyl phorbol-13-
acetate (Sigma, USA). Other cell lines were maintained 
in DMEM supplemented with 10% FBS in a 5% CO2 
atmosphere.
Reverse transcription and quantitative PCR
RNA extraction and cDNA synthesis were 
performed as described previously [21]. Quantitative 
PCR was performed with FastStart Universal SYBR 
Green Master with Rox (Roche) on a 7500 FAST (Applied 
Biosystems). Each PCR assay was run in triplicate for 
checking PCR variations. Expression levels of the target 
genes were normalized to that of hypoxanthine guanine 
phosphoribosyl transferase (Hprt). The primers used were: 
human LSF, tggcttcaacagttcccata and tctggctggtggtttggt; 
mouse Lsf, cccctccagtcacggataa and gcctcgtgaatgtggagaac; 
human HPRT, tgacactggcaaaacaatgca and 
ggtccttttcaccagcaagct; mouse Hprt, tcctcctcagaccgctttt 
and cctggttcatcatcgctaatc; human p21CIP1, 
ggcagaccagcatgacagatt and gcggattagggcttcctctt; mouse 
p21CIP1, gaacatctcagggccgaaaa and ctcccgtgggcacttcag.
Immunoblot analysis.
Proteins were extracted from approximately 107 
cells with Cell-LyEx2 according to the instructions of 
the manufacturer (TOYO B-net). Protein concentrations 
were determined using a BCA Protein Assay Kit (Pierce), 
and equal quantities were separated under reducing 
conditions on precast 10% NuPAGE Novex Bis–Tris Gels 
(Invitrogen) with NuPAGE®  MOPS SDS running buffer 
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containing 0.5% NuPAGE® antioxidant. Separated proteins 
were then transferred to FluoroTrans® PVDF transfer 
membranes (Pall) with the XCell II semi-wet blotting 
module (Invitrogen) according to the manufacturer’s 
instructions. The membranes were blocked with 5% (w/v) 
nonfat dry milk in 0.05% (v/v) Tween 20-Tris-buffered 
saline (TBS-T) at room temperature (RT) for 30 min and 
then probed with the following primary antibodies diluted 
with Can Get Signal 1 (Toyobo): anti-LSF (ab42973, 
Abcam; 1:2000), anti-α-tubulin (T9026, Sigma-Aldrich; 
1:10000), anti-cyclin B1 (#4135, Cell Signaling; 1:1000), 
anti-cyclin E (#4129, Cell Signaling; 1:1000), anti-p16 
(#4826, Cell Signaling; 1:1000), anti-p21 (ab7960, 
Abcam; 1:1000), anti-AKT (#9272, Cell Signaling; 
1:1000), anti-phosphorylated-AKT (#9271, Cell Signaling; 
1:1000), anti-FAK (#3285, Cell Signaling; 1:1000) 
and anti-phosphorylated-AKT (#3283, Cell Signaling; 
1:1000). The membranes were washed three times with 
TBS-T and then incubated with peroxidase-conjugated 
secondary anti-rabbit or anti-mouse IgG (#401315 
or #401215, Calbiochem; 1:10000) at RT for 1 hour. 
After washing, protein bands were visualized using the 
Luminata Crescendo Western HRP substrate (Millipore) 
and captured with an LAS3000 Imager (GE Healthcare).
Immunostaining and tissue microarray
All specimens were fixed in 4% paraformaldehyde 
in PBS (pH 6.8) and embedded in paraffin wax. 
Sections were cut at 5 µm and placed on Amino Silane-
coated glass slides (Matsunami). After drying at 60ºC, 
the slides were deparaffinized using standard protocols. 
Melanin was bleached following a routine method [22]. 
For antigen retrieval, slides were boiled in citrate buffer 
at pH 6.0 for 20 min and allowed to cool down to RT. 
Endogenous peroxidase was quenched with 3% H2O2 in 
methanol at RT for 20 min. After washing twice in PBS, 
slides were blocked with the host animal serum of the 
secondary antibody, incubated with the primary anti-LSF 
(ab42973, Abcam; 1:500), anti-Ki67 (ab66155, Abcam; 
1:200), anti-DCT (sc-10451, Santa Cruz; 1:400) and anti-
CD34 (ab8135, Abcam; 1:200) antibodies at 4 ºC for 18 
h, and washed in PBS. LSF and Ki67 were detected by 
using the Vectastain Elite ABC Kit and diaminobenzidine 
(Vector Laboratories). DCT and CD34 were detected by 
using Alexa-488 or -568-conjugated secondary antibodies. 
The human melanoma tissue array (ME1003), which 
contains samples from 56 cases of melanoma, 20 cases 
of metastatic melanoma in lymph nodes, and 24 cases of 
benign nevus was purchased from US Biomax and used to 
assess LSF expression as described above. Images were 
captured using an Olympus BX40 microscope, and the 
signal intensity was determined using WinROOF (Mitani) 
software. For each sample, the average intensity of the 
brown signal in each tumor area was calculated and LSF 
expression level in each tumor was classified into three 
groups, negative/weak, moderate or strong.
Construction of vectors, stable cell lines and cell 
proliferation assay
The full-length open reading frame of LSF was 
amplified from cDNA of the normal human fibroblast cell 
line MRC-5 by using PrimeSTAR MAX DNA polymerase 
(Takara) and was cloned into pDsRed-monomer-N1 
(Clontech) or pCMV-n-FLAG derived from pRK5 (BD 
Pharmingen) with the in-Fusion HD Cloning Kit (Takara). 
A 1521-bp fragment from -1520 to the transcription 
start site of human p21CIP1 was generated by PCR using 
genomic DNA from MRC-5 cells and then inserted into 
pGL4.17 (Promega) in the same way. 
SK-Mel28 and B16F10 cell clones that stably 
express DsRed-LSF or FLAG-LSF were generated by co-
transfecting the corresponding expression constructs and 
a puromycin selection vector using Lipofectamine® LTX 
(Invitrogen) and by selection with 10 µg/ml puromycin. 
Empty pDsRed-monomer-N1 and pCMV-n-FLAG vectors 
were used to establish control clones. Equal numbers (2 
x 105) of established cell lines were plated into 10 cm 
culture dishes, and the cell number was determined by 
hemocytometer counting at 0, 1, 2, 3, 4, 5 and 6 days.
Transient transfection, cell proliferation assay 
and flow cytometry
SK-Mel28 cells plated at 1.0 x 105 cells/well in 
six-well plates were allowed to attach to the bottom of 
the plate overnight and were then transiently transfected 
with 1-3 µg LSF-DsRed, LSF-FLAG or control vectors 
using Lipofectamine® LTX (Invitrogen). Two days after 
transfection, cell growth was determined by using the 
crystal violet (CV) assay as described previously [23]. For 
knockdown of LSF, 50 pmol of LSF siRNA (Invitrogen) 
was transfected using Lipofectamine® 2000 (Invitrogen). 
For flow cytometric analysis, transiently transfected 
cells were harvested by trypsinization two days later, 
washed three times with PBS, and fixed with 70% cold 
ethanol before staining with 5 µg/ml propidium iodide 
(Sigma-Aldrich) solution in the presence of 50 µg/ml 
RNase A at 37 ºC for 30 min. At least 50,000 events were 
analyzed for each sample using a FACSCalibur (BD 
Biosciences) and the cell cycle profiles were determined 
using FlowJo software (Tree Star, Inc.). All experiments 
were performed in triplicate.
In vivo tumorigenicity
A total of 107 B16F10 melanoma cells stably 
expressing the FLAG-LSF fusion protein (sB16-
FLAG-LSF cells) and control sB16-FLAG cells were 
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subcutaneously injected into 4-week-old nude mice with 
a Balb/c background. Tumor growth was monitored 
using Vernier calipers for 5-11 weeks before sacrifice for 
histochemical examination. 
Electrophoretic mobility shift assay (EMSA)
Oligonucleotides and their complements 
(Supplemental Table 1) were synthesized (Operon) with 
or without biotin end-labeling. The LSF binding sequence 
from the SV40 promoter was used as a positive control 
[24]. After mixing, each oligonucleotide pair was boiled at 
100ºC and cooled down to RT for annealing. Recombinant 
LSF protein was prepared using the TnT SP6 Coupled 
Reticulocyte Lysate System (Promega). EMSA was 
performed using the LightShift Chemiluminescent EMSA 
kit (Thermo Scientific) according to the manufacturer’s 
instructions. DNA-protein complexes were separated 
by electrophoresis on 7% PAGE in 0.5 x TBE buffer, 
transferred to Hybond-n+ (GE Healthcare), and visualized 
using the Chemiluminescent Nucleic Acid Detection 
Module (Thermo Scientific). 
Luciferase assay
SK-Mel28 cells stably expressing DsRed-LSF fusion 
protein and a control clone were grown to 70% confluence 
in 12-well plates and then transiently transfected with 
900 ng of firefly luciferase reporter plasmid (human 
p21CIP1 promoter cloned into pGL4.12) and 100 ng of 
Renilla luciferase control plasmid (EF-1α promoter 
cloned into the pRL-null vector) using Lipofectamine 
LTX (Invitrogen). For the siRNA experiment, 50 pmol 
of LSF siRNA (Invitrogen) was also co-transfected using 
Lipofectamine®2000 (Invitrogen). The cells were lysed 48 
hrs after transfection and luciferase activity was measured 
by using an LB9507 luminometer (Berthold) and the Dual-
luciferase Assay Kit (Promega). All experiments were 
performed in triplicate.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays 
using anti-DsRed antibody (Clontech) and quantification 
of precipitated DNA were performed as described 
previously [21]. Primers used were: p21(-2000), 
gcgacagggctgggatctgatgc and ccagacacactctaagggaggac; 
p21(-1500), gcagtggggcttagagtgggg and 
gcagacccccttggcctgcctcg; p21(-1000), 
ggtagatgggagcggatagacac and gcctcctgcccggggctctctgc; 
p21(-500), gttggggtgtctaggtgctccag and 
caccgctgacccactctggcaggc; p21(-1), ggccccggggagggcggtc 
and gatatacaaccgccccgcc.
Statistics
Student’s t-test was used for statistical analysis 
except for the results shown in Figure 2. Fisher’s exact 
test was used for statistical analysis of the data shown in 
Figure 2. 
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